Search

Author/Creator Miller, Kurt

1. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Issue 2 (February 2015)

Authors:
Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; Taplin, Mary-Ellen; Higano, Celestia S; de Souza, Paul; de Bono, Johann S; Griffin, Thomas W; ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 2(2015:Feb.)
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Issue 2 (February 2015)

Authors:
Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; Taplin, Mary-Ellen; Higano, Celestia S; de Souza, Paul; de Bono, Johann S; Griffin, Thomas W; ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 2(2015:Feb.)
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 3 (March 2019)

Authors:
Smith, Matthew; Parker, Chris; Saad, Fred; Miller, Kurt; Tombal, Bertrand; Ng, Quan Sing; Boegemann, Martin; Matveev, Vsevolod; Piulats, Josep Maria; Zucca, Luis Eduardo; Karyakin, Oleg; Kimura, Go; Matsubara, Nobuaki; Nahas, William Carlos; Nolè, Franco; Rosenbaum, Eli; Heidenreich, Axel; Kakehi...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 3(2019)
Page Start:
408
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. (4th November 2015)

Authors:
Beer, Tomasz M; Vogelzang, Nicholas; Bartůňková, Jiřina; Miller, Kurt; Oh, William; Oudard, Stephane; Pandha, Hardev; Sartor, A Oliver; Špíšek, Radek; Toole, Timothy O; Borgstein, Niels G; Gerritsen, Winald R
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. Issue 2 (December 2015)

Authors:
Beer, Tomasz; Vogelzang, Nicholas; Bartůňková, Jiřina; Miller, Kurt; Oh, William; Oudard, Stephane; Pandha, Hardev; Sartor, A; Špíšek, Radek; Toole, Timothy; Borgstein, Niels; Gerritsen, Winald
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Complications, functional and quality of life outcomes following primary and secondary implantation of penile prosthesis at a tertiary referral center. Issue 2 (April 2018)

Authors:
Ralla, Bernhard; Goranova, Irena; Börnstein, Niels; Friedersdorff, Frank; Maxeiner, Andreas; Magheli, Ahmed; Hinz, Stefan; Neymeyer, Joerg; Miller, Kurt; Busch, Jonas
Journal:
International journal of impotence research
Issue:
Volume 30:Issue 2(2018)
Page Start:
49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Issue 5 (May 2015)

Authors:
Loriot, Yohann; Miller, Kurt; Sternberg, Cora N; Fizazi, Karim; De Bono, Johann S; Chowdhury, Simon; Higano, Celestia S; Noonberg, Sarah; Holmstrom, Stefan; Mansbach, Harry; Perabo, Frank G; Phung, De; Ivanescu, Cristina; Skaltsa, Konstantina; Beer, Tomasz M; Tombal, Bertrand
Journal:
Lancet oncology
Issue:
Volume 16:Issue 5(2015:May)
Page Start:
509
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). (June 2015)

Authors:
Miller, Kurt; Simson, Gabriele; Goble, Sandra; Persson, Bo-Eric
Journal:
Therapeutic advances in urology
Issue:
Volume 7:Number 3(2015:Jun.)
Page Start:
105
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Enzalutamide in European and North American men participating in the AFFIRM trial. (23rd October 2014)

Authors:
Merseburger, Axel S.; Scher, Howard I.; Bellmunt, Joaquim; Miller, Kurt; Mulders, Peter F.A.; Stenzl, Arnulf; Sternberg, Cora N.; Fizazi, Karim; Hirmand, Mohammad; Franks, Billy; Haas, Gabriel P.; de Bono, Johann; de Wit, Ronald
Journal:
BJU international
Issue:
Volume 115:Number 1(2015:Jan.)
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗